{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T20:31:14Z","timestamp":1792528274002,"version":"4.5.0"},"reference-count":187,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.117904","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:08:00Z","timestamp":1750964880000},"page":"117904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Small molecular inhibitors targeting Janus kinases (JAKs) for the treatment of psoriasis"],"prefix":"10.1016","volume":"297","author":[{"given":"Dongna","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejmech.2025.117904_bib1","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jaad.2013.08.042","article-title":"Research gaps in psoriasis: opportunities for future studies","volume":"70","author":"Ryan","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"23","key":"10.1016\/j.ejmech.2025.117904_bib3","doi-asserted-by":"crossref","first-page":"13554","DOI":"10.1111\/jcmm.15742","article-title":"Overview of the molecular determinants contributing to the expression of psoriasis and psoriatic arthritis phenotypes","volume":"24","author":"Caputo","year":"2020","journal-title":"J. Cell Mol. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117904_bib4","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.3390\/ijms22094983","article-title":"Psoriasis: from pathogenesis to pharmacological and nano-technological-based therapeutics","volume":"22","author":"Petit","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117904_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122991","article-title":"Advances in psoriasis research: from pathogenesis to therapeutics","volume":"355","author":"Sugumaran","year":"2024","journal-title":"Life Sci."},{"issue":"19","key":"10.1016\/j.ejmech.2025.117904_bib6","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117904_bib7","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.3390\/ijms22094344","article-title":"Exploring the role of IL-36 cytokines as a new target in psoriatic disease","volume":"22","author":"Iznardo","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117904_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib9","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib10","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.abd.2023.03.001","article-title":"JAK-STAT pathway inhibitors in dermatology","volume":"98","author":"Miot","year":"2023","journal-title":"An. Bras. Dermatol."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117904_bib11","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1002\/jcp.29593","article-title":"Janus kinase inhibitors: a therapeutic strategy for cancer and autoimmune diseases","volume":"235","author":"Hosseini","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","article-title":"The immunology of psoriasis-current concepts in pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117904_bib13","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1016\/j.jid.2024.05.015","article-title":"Paradoxical psoriasis: an updated review of clinical features, pathogenesis, and treatment options","volume":"144","author":"Maronese","year":"2024","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib14","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/bjd.20963","article-title":"The biological basis of disease recurrence in psoriasis: a historical perspective and current models","volume":"186","author":"Puig","year":"2022","journal-title":"Br. J. Dermatol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib15","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","article-title":"Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis","volume":"84","author":"Thomas","year":"2024","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117904_bib17","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ejmech.2025.117904_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115195","article-title":"Advances in the development of phosphodiesterase-4 inhibitors","volume":"250","author":"Li","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115848","article-title":"Synthesis and clinical application of small-molecule inhibitors of janus kinase","volume":"261","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113633","article-title":"Application of carbohydrates in approved small molecule drugs: a review","volume":"223","author":"Jiang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117904_bib21","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"10275","key":"10.1016\/j.ejmech.2025.117904_bib22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117904_bib23","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cyto.2018.08.025","article-title":"Differential efficacy of biologic treatments targeting the TNF-\u03b1\/IL-23\/IL-17 axis in psoriasis and psoriatic arthritis","volume":"111","author":"Furue","year":"2018","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.117904_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/2324400","article-title":"Role of janus kinase (JAK) inhibitor in autoimmune ocular inflammation: a systematic review","volume":"2021","author":"Wen","year":"2021","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117904_bib26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","article-title":"JAK inhibitors for rheumatoid arthritis","volume":"32","author":"Kubo","year":"2023","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117904_bib27","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1535-7163.MCT-22-0323","article-title":"JAK: not just another kinase","volume":"21","author":"Agashe","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"issue":"Supple 2","key":"10.1016\/j.ejmech.2025.117904_bib28","doi-asserted-by":"crossref","first-page":"ii45","DOI":"10.1093\/rheumatology\/keaa896","article-title":"JAK1 inhibition and inflammatory bowel disease","volume":"60","author":"Harris","year":"2021","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117904_bib29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/ajh.26920","article-title":"JAK2 unmutated erythrocytosis: 2023 update on diagnosis and management","volume":"98","author":"Gangat","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"18","key":"10.1016\/j.ejmech.2025.117904_bib30","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.2174\/1389557519666190617152011","article-title":"Current status in the discovery of covalent janus kinase 3 (JAK3) inhibitors","volume":"19","author":"Dai","year":"2019","journal-title":"Mini Rev. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117904_bib31","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/17512433.2023.2219054","article-title":"TYK2 as a novel therapeutic target in psoriasis","volume":"16","author":"Elyoussfi","year":"2023","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117904_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116783","article-title":"STATs, promising targets for the treatment of autoimmune and inflammatory diseases","volume":"277","author":"He","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112155","article-title":"Janus kinases (JAKs): the efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders","volume":"192","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117904_bib34","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/08830185.2023.2274576","article-title":"STATs signaling pathways in dendritic cells: as potential therapeutic targets?","volume":"43","author":"Sohrabi","year":"2024","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.ejmech.2025.117904_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1075192","article-title":"Molecular dissection of Janus kinases as drug targets for inflammatory diseases","volume":"13","author":"Kwon","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117904_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103276","article-title":"JAK inhibitors and autoimmune rheumatic diseases","volume":"22","author":"Benucci","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"17","key":"10.1016\/j.ejmech.2025.117904_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713313","article-title":"Challenges and future trends in the treatment of psoriasis","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117904_bib38","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117904_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00035-19","article-title":"Infectious complications of biological and small molecule targeted immunomodulatory therapies","volume":"33","author":"Davis","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib40","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/1574886315666200128095958","article-title":"Treatment of psoriasis: a comprehensive review of entire therapies","volume":"15","author":"Bakshi","year":"2020","journal-title":"Curr. Drug Saf."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/pharmaceutics16010023","article-title":"Phosphodiesterase-4 inhibition in the management of psoriasis","volume":"16","author":"Crowley","year":"2023","journal-title":"Pharmaceutics"},{"issue":"19","key":"10.1016\/j.ejmech.2025.117904_bib42","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.3390\/cells12192352","article-title":"The role of sphingolipids and Sphingosine-1-phosphate-Sphingosine-1-phosphate-receptor signaling in psoriasis","volume":"12","author":"Masuda-Kuroki","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/13543776.2017.1236918","article-title":"ROR\u03b3 antagonists and inverse agonists: a patent review","volume":"27","author":"Bronner","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1586\/17474086.2.1.17","article-title":"Lestaurtinib: a multi-targeted FLT3 inhibitor","volume":"2","author":"Fathi","year":"2009","journal-title":"Expert Rev. Hematol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib45","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/s41375-021-01177-6","article-title":"FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: children's oncology group trial AALL0631","volume":"35","author":"Brown","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/pharmaceutics16020239","article-title":"New and emerging oral\/topical small-molecule treatments for psoriasis","volume":"16","author":"Carmona-Rocha","year":"2024","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117904_bib47","doi-asserted-by":"crossref","first-page":"adv00032","DOI":"10.2340\/00015555-3386","article-title":"Psoriasis and treatment: past, present and future aspects","volume":"100","author":"Reid","year":"2020","journal-title":"Acta Derm. Venereol."},{"issue":"20","key":"10.1016\/j.ejmech.2025.117904_bib48","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.3390\/jcm12206690","article-title":"Janus kinase inhibitors in rheumatoid arthritis: an update on the efficacy and safety of tofacitinib, baricitinib and upadacitinib","volume":"12","author":"Harrington","year":"2023","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117904_bib49","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of janus kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117904_bib50","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/17474124.2020.1780120","article-title":"JAK selectivity: more precision less troubles","volume":"14","author":"Roda","year":"2020","journal-title":"Expet Rev. Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib51","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117904_bib52","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117904_bib53","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1039\/C7MD00568G","article-title":"Design, synthesis and evaluation of (R)-3-(7-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor","volume":"9","author":"Chough","year":"2018","journal-title":"Medchemcomm"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117904_bib54","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117904_bib55","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.bmc.2018.01.021","article-title":"Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(methyl(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor","volume":"26","author":"Chough","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib56","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib57","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12865-020-00365-w","article-title":"JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells","volume":"21","author":"Fujita","year":"2020","journal-title":"BMC Immunol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib58","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","article-title":"JAK inhibitors (JAKi): mechanisms of action and perspectives in systemic and autoimmune diseases","volume":"46","author":"Chikhoune","year":"2025","journal-title":"Rev. Med. Interne"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib59","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ejmech.2025.117904_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113206","article-title":"Systematic comparison of competitive and allosteric kinase inhibitors reveals common structural characteristics","volume":"214","author":"Hu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"45","key":"10.1016\/j.ejmech.2025.117904_bib61","doi-asserted-by":"crossref","first-page":"27261","DOI":"10.1074\/jbc.M115.672048","article-title":"Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2)","volume":"290","author":"Min","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110434","article-title":"Recent progress on tyrosine kinase 2 JH2 inhibitors","volume":"121","author":"Deng","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2025.117904_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104488","article-title":"Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases","volume":"89","author":"Yuan","year":"2023","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.ejmech.2025.117904_bib64","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/13543776.2022.2026927","article-title":"Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019-2021)","volume":"32","author":"Gonzalez Lopez de Turiso","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ajd.14391","article-title":"A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease","volume":"66","author":"Haggett","year":"2025","journal-title":"Australas. J. Dermatol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib66","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117904_bib67","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2025.117904_bib68","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1021\/jm1004286","article-title":"Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection","volume":"53","author":"Flanagan","year":"2010","journal-title":"J. Med. Chem."},{"issue":"14","key":"10.1016\/j.ejmech.2025.117904_bib69","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2217\/imt-2017-0087","article-title":"Tofacitinib in psoriatic arthritis","volume":"9","author":"Wang","year":"2017","journal-title":"Immunotherapy"},{"issue":"18","key":"10.1016\/j.ejmech.2025.117904_bib70","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1016\/j.bmc.2018.08.005","article-title":"Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor","volume":"26","author":"Hamaguchi","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib71","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1248\/cpb.c15-00036","article-title":"Synthesis and evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as novel immunomodulators targeting Janus kinase 3","volume":"63","author":"Nakajima","year":"2015","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib72","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/14397595.2020.1794103","article-title":"Efficacy and safety of peficitinib in rheumatoid arthritis","volume":"30","author":"Kaneko","year":"2020","journal-title":"Mod. Rheumatol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117904_bib73","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/jdv.18263","article-title":"The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis-A network meta-analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib74","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrd3652","article-title":"Ruxolitinib","volume":"11","author":"Mesa","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib75","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/1346-8138.17510","article-title":"Oral administration of ruxolitinib in psoriasis vulgaris: a case report of plaque psoriasis accompanied by myelofibrosis secondary to polisitemia vera successfully treated with oral ruxolitinib","volume":"52","author":"\u00c7etinarslan","year":"2025","journal-title":"J. Dermatol."},{"issue":"13","key":"10.1016\/j.ejmech.2025.117904_bib76","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib77","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/14740338.2020.1743263","article-title":"The safety of baricitinib in patients with rheumatoid arthritis","volume":"19","author":"Honda","year":"2020","journal-title":"Expet Opin. Drug Saf."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117904_bib78","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117904_bib79","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"19","key":"10.1016\/j.ejmech.2025.117904_bib80","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117904_bib81","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard-2024-225534","article-title":"Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"83","author":"Kerschbaumer","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117904_bib82","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, Double-Blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002735","article-title":"Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis","volume":"9","author":"Burmester","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib84","first-page":"275","article-title":"Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-Year results from the phase 3 SELECT-PsA 1 Study","volume":"10","author":"McInnes","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"22","key":"10.1016\/j.ejmech.2025.117904_bib85","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1021\/jm501262q","article-title":"Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634","volume":"57","author":"Menet","year":"2014","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117904_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003550","article-title":"Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial","volume":"9","author":"Chandran","year":"2023","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib87","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/13543784.2023.2207737","article-title":"Recent developments for new investigational JAK inhibitors in psoriatic arthritis","volume":"32","author":"Caso","year":"2023","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117904_bib88","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib89","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jaip.2023.03.011","article-title":"Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations","volume":"11","author":"Butala","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib90","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40262-021-01104-z","article-title":"Population pharmacokinetics of abrocitinib in healthy individuals and patients with psoriasis or atopic dermatitis","volume":"61","author":"Wojciechowski","year":"2022","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib91","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br. J. Dermatol."},{"issue":"36","key":"10.1016\/j.ejmech.2025.117904_bib92","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1080\/14796694.2024.2396795","article-title":"Safety and efficacy of itacitinib, a selective JAK1 inhibitor, in advanced hepatocellular cancer: phase 1b trial (JAKAL)","volume":"20","author":"Troiani","year":"2024","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2025.117904_bib93","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9949961","article-title":"Novel pharmacological treatment options of steroid-refractory graft-versus-host disease","volume":"2023","author":"Kovalenko","year":"2023","journal-title":"Adv Hematol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117904_bib94","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/jcph.1601","article-title":"The effect of renal impairment on the pharmacokinetics and safety of itacitinib","volume":"60","author":"Srinivas","year":"2020","journal-title":"J. Clin. Pharmacol."},{"issue":"20","key":"10.1016\/j.ejmech.2025.117904_bib95","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.2174\/0929867330666230324163414","article-title":"Targeting TYK2 for fighting diseases: recent advance of TYK2 inhibitors","volume":"31","author":"Du","year":"2024","journal-title":"Curr. Med. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2025.117904_bib96","doi-asserted-by":"crossref","first-page":"13561","DOI":"10.1021\/acs.jmedchem.0c00948","article-title":"Discovery of tyrosine kinase 2 (TYK2) inhibitor (PF-06826647) for the treatment of autoimmune diseases","volume":"63","author":"Gerstenberger","year":"2020","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib97","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study","volume":"87","author":"Tehlirian","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117904_bib98","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1016\/S2665-9913(20)30397-0","article-title":"Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study","volume":"3","author":"Tehlirian","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib99","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/cts.12929","article-title":"Safety and pharmacokinetics of the oral TYK2 inhibitor PF-06826647: a phase I, randomized, double-blind, placebo-controlled, dose-escalation study","volume":"14","author":"Singh","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.ejmech.2025.117904_bib100","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejmech.2013.03.070","article-title":"Lead identification of novel and selective TYK2 inhibitors","volume":"67","author":"Liang","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117904_bib101","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1021\/jm400266t","article-title":"Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors","volume":"56","author":"Liang","year":"2013","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117904_bib102","doi-asserted-by":"crossref","first-page":"8545","DOI":"10.1021\/acs.jmedchem.4c00769","article-title":"Discovery of GLPG3667, a selective ATP competitive tyrosine kinase 2 inhibitor for the treatment of autoimmune diseases","volume":"67","author":"Mammoliti","year":"2024","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib103","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/acs.jmedchem.5b01857","article-title":"Structure-based design and synthesis of 3-Amino-1,5-dihydro-4H-pyrazolopyridin-4-one derivatives as tyrosine kinase 2 inhibitors","volume":"59","author":"Yogo","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib104","article-title":"JAK inhibitors: is specificity at all relevant?","volume":"64S","author":"Gadina","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2025.117904_bib105","doi-asserted-by":"crossref","first-page":"10959","DOI":"10.1021\/acs.jmedchem.3c00926","article-title":"Progress on the pharmacological targeting of janus pseudokinases","volume":"66","author":"Henry","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104840","article-title":"Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors","volume":"97","author":"Jensen","year":"2023","journal-title":"EBioMedicine"},{"issue":"20","key":"10.1016\/j.ejmech.2025.117904_bib107","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1021\/acs.jmedchem.9b00443","article-title":"Identification of N-Methyl nicotinamide and N-Methyl Pyridazine-3-Carboxamide pseudokinase domain ligands as highly selective allosteric inhibitors of tyrosine kinase 2 (TYK2)","volume":"62","author":"Moslin","year":"2019","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib108","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib109","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program fOr evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"20","key":"10.1016\/j.ejmech.2025.117904_bib110","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib111","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41573-024-00914-7","article-title":"The landscape of small-molecule prodrugs","volume":"23","author":"Fralish","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"issue":"22","key":"10.1016\/j.ejmech.2025.117904_bib112","doi-asserted-by":"crossref","first-page":"20664","DOI":"10.1021\/acs.jmedchem.4c02219","article-title":"Prodrug strategy to address impaired oral absorption of a weakly basic TYK2 inhibitor caused by a gastric acid-reducing agent","volume":"67","author":"Subbaiah M","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117904_bib113","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1039\/C6MD00560H","article-title":"Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling","volume":"8","author":"Moslin","year":"2016","journal-title":"Medchemcomm"},{"issue":"17","key":"10.1016\/j.ejmech.2025.117904_bib114","doi-asserted-by":"crossref","first-page":"11061","DOI":"10.1074\/jbc.M114.619502","article-title":"Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain","volume":"290","author":"Tokarski","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.ejmech.2025.117904_bib115","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1021\/acs.jmedchem.3c00600","article-title":"Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-279","volume":"66","author":"Leit","year":"2023","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117904_bib116","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib117","doi-asserted-by":"crossref","first-page":"i1853","DOI":"10.1093\/ecco-jcc\/jjae190.1175","article-title":"P1001 efficacy and safety of an oral tyrosine kinase 2 inhibitor VTX958 in moderately to severely active Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Danese","year":"2025","journal-title":"Journal of Crohn's and Colitis"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117904_bib118","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70094","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study design","volume":"17","author":"Ucpinar","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117904_bib119","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1021\/acs.jmedchem.1c00217","article-title":"Synthetic opportunities and challenges for macrocyclic kinase inhibitors","volume":"64","author":"Amrhein","year":"2021","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2025.117904_bib120","doi-asserted-by":"crossref","first-page":"14768","DOI":"10.1021\/acs.jmedchem.4c01163","article-title":"The missing link(er): a roadmap to macrocyclization in drug discovery","volume":"67","author":"Brudy","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib121","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116501","article-title":"Macrocyclization strategy for improving candidate profiles in medicinal chemistry","volume":"272","author":"Darlami","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib122","article-title":"Preparation of macrocycles as TYK2 inhibitors and uses thereof","author":"Jin","year":"2020","journal-title":"WO2020185755A1"},{"key":"10.1016\/j.ejmech.2025.117904_bib123","article-title":"Pyridazinoimidazole-benzotriazole macrolactam derivatives as TYK2 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases","author":"Jin","year":"2022","journal-title":"WO2022060973A1"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib124","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12964-023-01299-7","article-title":"A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways","volume":"21","author":"Chen","year":"2023","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2025.117904_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129838","article-title":"Discovery of a potent and selective JAK1-targeting PROTAC degrader with anti-tumor activities","volume":"109","author":"Zhang","year":"2024","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"6589","key":"10.1016\/j.ejmech.2025.117904_bib126","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117904_bib127","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1471-2164-11-199","article-title":"Transcriptome analysis reveals a major impact of JAK protein tyrosine kinase 2 (Tyk2) on the expression of interferon-responsive and metabolic genes","volume":"11","author":"Vogl","year":"2010","journal-title":"BMC Genom."},{"issue":"39","key":"10.1016\/j.ejmech.2025.117904_bib128","doi-asserted-by":"crossref","first-page":"33811","DOI":"10.1074\/jbc.M111.270207","article-title":"Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-Associated tyrosine kinase Tyk2","volume":"286","author":"Piganis","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117904_bib129","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","article-title":"TYK2: an emerging therapeutic target in rheumatic disease","volume":"20","author":"Morand","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib130","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117904_bib131","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting chimeras (PROTACs) - past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117904_bib132","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1111\/bph.15014","article-title":"Proteolysis-targeting chimeras in drug development: a safety perspective","volume":"177","author":"Moreau","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"16","key":"10.1016\/j.ejmech.2025.117904_bib133","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral estrogen receptor PROTAC vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4\/6 or PI3K\/mTOR pathway inhibitors in preclinical ER+ breast cancer models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib134","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","article-title":"Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer","volume":"36","author":"Rathkopf","year":"2025","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117904_bib135","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1021\/acsmedchemlett.2c00334","article-title":"Novel TYK2 inhibitors with an N-(Methyl-d3)pyridazine-3-carboxamide skeleton for the treatment of autoimmune diseases","volume":"13","author":"Liu","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117904_bib136","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1021\/acs.jmedchem.2c01800","article-title":"Development and therapeutic implications of tyrosine kinase 2 inhibitors","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129083","article-title":"Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor","volume":"79","author":"Kato","year":"2023","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117904_bib138","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1021\/acs.jmedchem.5c00027","article-title":"Discovery of a highly potent and selective tyrosine kinase 2 (TYK2) degrader with in vivo therapeutic efficacy in a murine psoriasis model","volume":"68","author":"Xiong","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112981","article-title":"Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: recent progress and future challenges","volume":"210","author":"Zeng","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105848","article-title":"Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery","volume":"125","author":"Xi","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib141","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician","volume":"20","author":"Szekanecz","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib142","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/bjd\/ljae014","article-title":"Deucravacitinib in plaque psoriasis: 2-Year safety and efficacy results from the phase III POETYK trials","volume":"190","author":"Lebwohl","year":"2024","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117904_bib143","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1007\/s11030-023-10794-5","article-title":"Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship","volume":"28","author":"Maji","year":"2024","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2025.117904_bib144","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ymeth.2016.04.007","article-title":"Biochemical and cell biological assays to identify and characterize DNA helicase inhibitors","volume":"108","author":"Banerjee","year":"2016","journal-title":"Methods"},{"key":"10.1016\/j.ejmech.2025.117904_bib145","article-title":"Biochemical assays for analyzing activities of ATP-Dependent chromatin remodeling enzymes","volume":"92","author":"Chen","year":"2014","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.ejmech.2025.117904_bib146","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-1-62703-242-1_3","article-title":"In vitro JAK kinase activity and inhibition assays","volume":"967","author":"Babon","year":"2013","journal-title":"Methods Mol. Biol."},{"issue":"Pt 2","key":"10.1016\/j.ejmech.2025.117904_bib147","article-title":"Discovery of furopyridine-based compounds as novel inhibitors of janus kinase 2: in silico and in vitro studies","volume":"260","author":"Suriya","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2025.117904_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107430","article-title":"Discovery of selective TYK2 inhibitors: design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold","volume":"148","author":"Istanbullu","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib149","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10408347.2014.881250","article-title":"Surface plasmon resonance (SPR) biosensors in pharmaceutical analysis","volume":"45","author":"Olaru","year":"2015","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib150","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/978-1-0716-1197-5_5","article-title":"Isothermal titration calorimetry","volume":"2263","author":"Johnson","year":"2021","journal-title":"Methods Mol. Biol."},{"issue":"24","key":"10.1016\/j.ejmech.2025.117904_bib151","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.3390\/s20247132","article-title":"Fluorescence polarization-based bioassays: new Horizons","volume":"20","author":"Hendrickson","year":"2020","journal-title":"Sensors (Basel)"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib152","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/ijms17020144","article-title":"Insights into protein-ligand interactions: mechanisms, models, and methods","volume":"17","author":"Du","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117904_bib153","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098800","article-title":"A comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determination","volume":"9","author":"Rudolf","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib154","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/2472555220923362","article-title":"Optimization of a high-throughput cell-based screening strategy to identify small-molecule inhibitors of IL-23 signaling","volume":"26","author":"Varghese","year":"2021","journal-title":"SLAS Discov"},{"issue":"11","key":"10.1016\/j.ejmech.2025.117904_bib155","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/art.42547","article-title":"Differences in JAK isoform selectivity among different types of JAK inhibitors evaluated for rheumatic diseases through in vitro profiling","volume":"75","author":"Virtanen","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117904_bib156","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1021\/acsmedchemlett.2c00411","article-title":"Optimization of pyrimidine compounds as potent JAK1 inhibitors and the discovery of R507 as a clinical candidate","volume":"13","author":"Chen","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117904_bib157","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117904_bib158","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","article-title":"Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis","volume":"95","author":"Wang","year":"2020","journal-title":"Mayo Clin. Proc."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib159","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"2S","key":"10.1016\/j.ejmech.2025.117904_bib160","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/j.jaad.2023.05.049","article-title":"Janus kinase inhibitors for alopecia areata","volume":"89","author":"King","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"issue":"34","key":"10.1016\/j.ejmech.2025.117904_bib161","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1: a phase III randomized trial of momelotinib versus ruxolitinib in Janus Kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"10281","key":"10.1016\/j.ejmech.2025.117904_bib162","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117904_bib163","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.3390\/nu17081323","article-title":"Recent advances in gut microbiota in psoriatic arthritis","volume":"17","author":"Bonomo","year":"2025","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.ejmech.2025.117904_bib164","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1111\/jdv.14949","article-title":"Generalized pustular psoriasis: a review and update on treatment","volume":"32","author":"Hoegler","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117904_bib165","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117904_bib166","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and pharmacodynamics of ruxolitinib: a review","volume":"62","author":"Appeldoorn","year":"2023","journal-title":"Clin. Pharmacokinet."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2025.117904_bib167","doi-asserted-by":"crossref","first-page":"105","DOI":"10.31138\/mjr.31.1.105","article-title":"Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors","volume":"31","author":"Bertsias","year":"2020","journal-title":"Mediterr J Rheumatol"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib168","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejmech.2025.117904_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113492","article-title":"Dual-target compounds for alzheimer's disease: natural and synthetic AChE and BACE-1 dual-inhibitors and their structure-activity relationship (SAR)","volume":"221","author":"Ferreira","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117465","article-title":"Combination therapy and dual-target inhibitors based on cyclin-dependent kinases (CDKs): emerging strategies for cancer therapy","volume":"289","author":"Hao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106181","article-title":"HDAC\/JAK dual target inhibitors of cancer-related targets: the success of nonclearable linked pharmacophore mode","volume":"129","author":"Zhao","year":"2022","journal-title":"Bioorg. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117904_bib172","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1021\/acs.jmedchem.3c00036","article-title":"Exploration of Janus Kinase (JAK) and histone deacetylase (HDAC) bispecific inhibitors based on the moiety of fedratinib for treatment of both hematologic malignancies and solid cancers","volume":"66","author":"Qiu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib173","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114551","article-title":"Dual-target Janus kinase (JAK) inhibitors: comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases","volume":"239","author":"Shen","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2025.117904_bib174","doi-asserted-by":"crossref","first-page":"19267","DOI":"10.1021\/acs.jmedchem.4c01681","article-title":"Discovery of Janus Kinase and histone deacetylase dual inhibitors as a new strategy to treat psoriasis","volume":"67","author":"Hu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117904_bib175","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117904_bib176","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/1744666X.2022.1993061","article-title":"Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis","volume":"18","author":"Fardos","year":"2022","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117904_bib177","first-page":"188","article-title":"Novel clinical applications of topical ruxolitinib: a case series","volume":"23","author":"Zundell","year":"2024","journal-title":"J. Drugs Dermatol. JDD"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117904_bib178","doi-asserted-by":"crossref","first-page":"664","DOI":"10.36849\/JDD.7268","article-title":"A review on the use of topical ruxolitinib for the treatment of vitiligo","volume":"22","author":"Grossmann","year":"2023","journal-title":"J. Drugs Dermatol. JDD"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117904_bib179","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"4","key":"10.1016\/j.ejmech.2025.117904_bib180","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/24755303231201336","article-title":"Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis","volume":"8","author":"Kingston","year":"2023","journal-title":"J. Psoriasis Psoriatic Arthritis"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117904_bib181","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"issue":"5","key":"10.1016\/j.ejmech.2025.117904_bib182","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: Cargo-specific degraders using selective autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol Cell"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib183","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2306682120","article-title":"Decreasing the intrinsically disordered protein \u03b1-synuclein levels by targeting its structured mRNA with a ribonuclease-targeting chimera","volume":"121","author":"Tong","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117904_bib184","doi-asserted-by":"crossref","first-page":"690","DOI":"10.3390\/molecules28020690","article-title":"Emerging TACnology: heterobifunctional small molecule inducers of targeted posttranslational protein modifications","volume":"28","author":"Heitel","year":"2023","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117904_bib185","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10529-017-2500-5","article-title":"Itaconic acid production in microorganisms","volume":"40","author":"Zhao","year":"2018","journal-title":"Biotechnol. Lett."},{"issue":"21","key":"10.1016\/j.ejmech.2025.117904_bib186","doi-asserted-by":"crossref","first-page":"9041","DOI":"10.1007\/s00253-020-10908-1","article-title":"Itaconic acid derivatives: structure, function, biosynthesis, and perspectives","volume":"104","author":"Sano","year":"2020","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"Pt B","key":"10.1016\/j.ejmech.2025.117904_bib187","article-title":"4-Octyl itaconate inhibits inflammation to attenuate psoriasis as an agonist of oxeiptosis","volume":"124","author":"You","year":"2023","journal-title":"Int. Immunopharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425006695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425006695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:55:02Z","timestamp":1776920102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425006695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":187,"alternative-id":["S0223523425006695"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117904","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small molecular inhibitors targeting Janus kinases (JAKs) for the treatment of psoriasis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117904"}}